


Actualities of Hungarian pharmaceutical financing market

Source: Healthware analysis based on NHIFA dat



Healthware Consulting Ltd.

H-1133 Budapest, Váci út 76. 7.em. 2. tor. + 36-1-324-2050

(in Subscribe



Toplists of reimbursement and num	ber of patients, April 202	24	
TOP 10 ATCs by all reimbursement paid			TOP 10 DOT by all reimbursement paid
semaglutide		1 398 M HUF 48	8,71 M colecalciferol
enoxaparin		1 391 M HUF	22,62 M perindopril and amlodipin
adalimumab		1 379 M HUF	22,09 M rosuvastatin
apixaban		1 356 M HUF	16,36 M perindopril and diuretics
ruxolitinib	12	232 M HUF	16,27 M pantoprazole
other nutrients	954 M HUF		11,59 M ramipril
rivaroxaban 665	M HUF		10,84 M nebivolol
palbociclib 648 M	M HUF	22%	10,30 M atorvastatin
enzalutamide 642 N	/I HUF		10,23 M amlodipine
insuline degludec and liraglutio 32 N	1 HUF		
urce: Pharmacy turnover data, Healthware analysis			Source: Pharmácy turnover data, Healthware analysis
OP 10 distributors by all reimbursement paid	1		TOP 10 patient turnover by all reimbursement paid
Novartis		4 417 M H	
Novo	3 006 M HU	F	377,133 pantoprazole
Pfizer	2 869 M HUF		271,336 duration and divertics 264,487
Richter	2 648 M HUF		240,057
Sanofi-Aventis	2 535 M HUF		220,648
Sandoz	2 449 M HUF		215,505 **********************************
Egis 2 097 M HUF			203,298 1 1 1 1 1 1 1 1 1 1
Boehringer 1 467 M HUF			203,190 ************************************
AstraZeneca 1 395 M HUF		52%	174,936
Teva 1 311 M HUF urce: Phormacy turnover data, Healthware analysis			174,868 ************************** amlodipine

Substitutable products, April 2024


Within product deletions, marketing authorization (MAH) erasures were distinguished.

We also examined the active substances and brands affected in the procedure. These were divided into two groups according to whether the brand or active substance was completely removed from the formulary or whether there remained (affected) at least one product that belonged to the active substance or brand.



Source: Pharmacy turnover data, Healthware analysis

Product shortage – Turnover data for preparations without equivalent*



*Equivalent substitutes established by the National Centre for Public Health and Pharmacy


**Turnover in the 12 months preceding the product shortage Source: Pharmacy turnover data, Healthware analysis

Healthware Consulting Ltd.

Number of reimbursed substitutes

The graph shows the distribution of the reimbursed product shortage list. **485 products** had been on the list before April 2024, compared to 34 new product added to the list in the month under review. The 53 newly listed products were grouped according to the number of reimbursed substitutes. Based on this criterion, **4**

groups were formed: products with 3 or more, exactly 2, exactly 1 and 0 reimbursed substitutes



Source: Pharmacy turnover data, Healthware analysis

Highest growth, April 2024 vs March 2024 in HUF

Product shortages

Ranking	Brand	Reimbursement increment	%*
1 NOVARTIS	LEQVIO	143 787 447 HUF	185%
² sanofi	LIBTAYO	129 613 206 HUF	141%
3 DANONE	NUTRICIA	99 494 335 HUF	350%
4 U NOVARTIS	JAKAVI	88 749 151 HUF	104%
5 S A N D O Z	HYRIMOZ	84 122 340 HUF	103%
6 Dailchi-Sankyo Passion for Innovation, Compassion for Patients."	LIXIANA	72 305 875 HUF	117%
7 the Bristol Myers Squibb	ELIQUIS	70 442 331 HUF	106%
8 Roche	ERIVEDGE	67 073 705 HUF	134%
9	RYBELSUS	60 662 985 HUF	126%
	KISQALI	58 651 125 HUF	113%

*Compared to the average of the 6 months preceding the reference month Source: Pharmacy turnover data, Healthware analysi.